The serotonin syndrome and its treatment

Journal of Psychopharmacology

Volumn 13, Issue 1, 1999, Pages 100-109

  Gillman, Peter Kenneth ^a  

^a NONE   (Australia)

Author keywords

Chlorpromazine; Cyproheptadine; Serotonin antagonists; Serotonin syndrome; Treatment

Indexed keywords

CHLORPROMAZINE; CHLORPROTHIXENE; CLOMIPRAMINE; CLOZAPINE; CYPROHEPTADINE; HALOPERIDOL; IMIPRAMINE; KETANSERIN; METHYSERGIDE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SERTINDOLE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEROTONIN SYNDROME;

EID: 0032999945     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119901300111     Document Type: Article

References (142)

1. Ames D, Wirshing W C (1993) Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome a possible link? JAMA 269: 869-870
2. Ananth J, Luchins A (1977) A review of combined tricyclic and MAOI therapy. Comp Psychiatry 18: 221-230
3. Arnett C D, Fowler J S, MacGregor R R, Schlyer D J, Wolf A P, Langstrom B, Halldin C (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-(11C) deprenyl. J Neurochem 49: 522-527
4. Ayd F J (1961a) A critique of antidepressants. Dis Nerv Syst 22:32-36
5. Ayd F J (1961b) Toxic somatic and psychopathologic reactions to antidepressant drugs. J Neuropsychiatr 2: 119-122
6. Babiak J (1961) A case fatality of overdose of a combination of tranylcypromine (parnate) and imipramine (tofranil). Can Med Assoc J 85: 377-378
7. Baetz M, Malcolm D (1995) Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry 40: 428-429
8. Beasley C M, Masica D N, Heiligenstein J H, Wheadon D E, Zerbe R L (1993) Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 13: 312-320
9. Beaumont G (1973) Drug interaction with clomipramine (anafranil). J Intern Med Res 1: 480-484
10. Bedford-Russel A R, Schwartz R H, Dawling S (1992) Accidental ingestion of 'ecstasy' (3,4-methylenedioxymethamphetamine). Arch Dis Child 67: 1114-1115
11. Benazzi F (1996) Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry 29: 162
12. Bodner R A, Lynch T, Lewis L, Kahn D (1995) Serotonin syndrome. Neurology 45: 219-223
13. Bogdanski D F, Weissbach H, Undenfriend S (1958) Pharmacological studies with the serotonin precursor 5-hydroxytryptophan. J Pharmacol Exp Ther 122: 182-194
14. Bowen L W (1964) Fatal hyperpyrexia with antidepressant drugs. BMJ 2: 14-65
15. Braitberg G (1994) Serotonin syndrome. Med J Aust 160: 527-528
16. Brannan S K,Talley B J, Bowden C J (1994) Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 14: 144-145
17. Brennan D, MacManus M, Howe J, McLoughlin J (1988) Neuroleptic malignant syndrome without neuroleptics. Br J Psychiatry 152: 578-579
18. Brodribb T R, Downey M, Gilbar P J (1994) Efficacy and adverse effects of moclobemide. Lancet 343: 475
19. Brown T M, Skop B P (1996) Nitroglycerine in the treatment of the serotonin syndrome. Ann Pharmacother 30: 191
20. Brown T M, Skop B P, Mareth T R (1996) Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 30: 527-533
21. Brownlee G, Williams G W (1961) Potentiation of amphetamine and pethidine by monoamine oxidase inhibitors. Lancet 1: 669
22. Brubacher J R (1997) Treating the serotonin syndrome: antidote or support. J Toxicol Clin Toxicol 35: 213-214
23. Brubacher J R, Hoffman R S, Lurin M J (1996) Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Human Toxicol 38: 358-361
24. Carlsson A, Lindqvist M (1969) Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines. J Pharm Pharmacol Chemother 21: 460-464
25. Carlsson A, Jonason J, Lindqvist M (1969) Demonstration of extra neuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res 12: 456-460
26. Caroff S N, Mann S C (1993) Neuroleptic malignant syndrome. Contemp Clin Neurol 77: 185-202
27. Ciocatto E, Fagiano G, Bava G L (1972) Clinical features and treatment of overdosage of monoamine oxidase inhibitors and their interaction with other psychotropic drugs. Resuscitation 1: 69-72
28. Clark W G, Lipton J M (1986) Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants: II. Neurosci Biobehav Rev 10: 153-220
29. Clement A J, Benazon D (1962) Reactions to other drugs in patients taking monoamine oxidase inhibitors. Lancet 2: 197-198
30. Cocks D P, Passmore-Rowe A H (1962) Dangers of monoamine oxidase inhibitors. BMJ 2: 1545-1546
31. Coplan D, Gorman J M (1993) Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 150: 837
32. Corkeron M A (1995) Serotonin syndrome a potentially fatal complication of antidepressant therapy. Med J Aust 163: 481-482
33. Curzon G, Ettlinger G, Cole M, Walsh J (1963) The biochemical, behavioral and neurologic effects of high L-tryptophan intake in the rhesus monkey. Neurology 12: 431-438
34. Denton P H, Borrelli V M, Edwards N V (1962) Dangers of monoamine oxidase inhibitors. BMJ 2: 1752-1753
35. Espelin D E, Done A K (1968) Amphetamine poisoning. N Engl J Med 278: 1361-1365
36. Fahim J, Ismail M, Osman O H (1972) The role of 5-hydroxytryptamine and noradrenaline in the hyperthermic reaction induced by pethidine in rabbits pretreated with pargyline. Br J Pharmacol 46: 414-416
37. Felner A E, Waldmeier P C (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28: 995-1002
38. Fjalland B (1979) Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxyamphetamine in MAOI pretreated rabbits. Psychopharmacology 63: 113-117
39. Francois B, Marquet P, Desachy A, Roustan J, Lachatre G, Gastinne H (1997) Serotonin syndrome due to an overdose of moclobemide and clomipramine: a potentially life threatening association. Intens Care Med 23: 122-124
40. Gander D R (1965) Treatment of depressive illness with combined antidepressants. Lancet 1: 107-109
41. George T P, Godleski L S (1996) Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry 39: 384-385
42. Gillman P K (1995) Possible serotonin syndrome with moclobemide and pethidine. Med J Aust 162: 554
43. Gillman P K (1996) Successful treatment of serotonin syndrome with chlorpromazine. Med J Aust 165: 345
44. Gillman P K (1997a) Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 167: 109-111
45. Gillman P K (1997b) Serotonin syndrome treated with chlorpromazine. J Clin Psychopharmacol 17: 128-129
46. Goldberg R J, Huk M (1992) Serotonin syndrome from trazadone and buspirone. Psychosomatics 33: 235-236
47. Goldberg R S, Thornton W E (1986) Combined tricyclic-MAOI therapy for refractory depression: a review with guidelines for appropriate usage. J Clin Pharmacol 18: 143-147
48. Graber M A, Hoehns T B, Perry P J (1994) Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 28: 732-735
49. Green A R, Grahame-Smith D G (1974) The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology 13: 949-959
50. Green A R, Grahame-Smith D G (1976) Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature 260: 487-491
51. Green A R, Cross A J, Goodwin G M (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxy-methamphetamine (MDMA or 'ecstasy'). Psychopharmacology 119: 247-260
52. Guze B H, Baxter L R (1986) The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol 6: 119-120
53. Halman M, Goldblum B S (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28: 518-521
54. Hansen T E, Dieter K, Keepers G A (1990) Interaction of fluoxetine and pentazocine. Am J Psychiatry 147: 949-950
55. Harker J, Gibson P (1995) Heat-stroke: a review of rapid cooling techniques. Intens Crit Care Nursing 11: 198-202
56. Harrer G (1961) Zur Inkompatibilitat zwischen Monoaminooxydasehemmern und Imipramin. Wien Med Wschr 111: 5-51
57. Heisler M A, Guidry J R, Arnecke B (1996) Serotonin syndrome induced by the administration of venlafaxine and phenelzine. Ann Pharmacother 30: 84
58. Hernandez A F, Montero M N, Pla A, Villanueva E (1995) Fatal moclobemide overdose or death caused by serotonin syndrome? J Forensic Sci 40: 128-130
59. Hess S M, Doepfner W (1961) Behavioural effects and brain amine content in rats. Arch Int Pharmacodyn Ther 134: 89-99
60. Hess S M, Redfield B G, Underfriend S (1959) The effect of monoamine oxidase inhibitors and tryptophan on the tryptamine content of animal tissues and urine. J Pharmacol Exp Ther 127: 178
61. Hilton S E, Maradit H, Moller H J (1997) Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 247: 113-119
62. Himwich W A (1962) Interaction of monoamine oxidase inhibitors with imipramine and similar drugs. Recent Adv Biol Psychiatry 4: 257
63. Himwich W A, Petersen J C (1961) Effect of the combined administration of imipramine and a monoamine oxidase inhibitor. Am J Psychiatry 117: 928-929
64. Hodgman M J, Martin T G, Krenzelok E P (1997) Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Human Exp Toxicol 16: 14-17
65. Horita A, Gogerty J H (1958) The pyretogenic effect of 5-hydroxytryptophan and its comparison with LSD. J Pharmacol Exp Ther 122: 195-200
66. Howarth E (1961) Possible synergistic effects of the new thymoleptics in connection with poisoning. J Ment Sci 707: 100-103
67. Insel T, Roy B, Cohen R, Murphy D (1982) Possible development of the serotonin syndrome in man. Am J Psychiatry 139: 954-955
68. Jahr J S, Pisto J D, Gitlin M C, O'Neill P T (1994) The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 79: 189-191
69. Jounela A J, Mattila M J, Knoll J (1977) Interaction of selective inhibitors of monoamine oxidase with pethidine in the rabbit. Biochem Pharmacol 26: 806-808
70. Kapur S, Zipursky R B, Jones C, Wilson A A, Dasilva J D, Houle S (1997) Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry 154: 884
71. Keltner N (1994) Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect Psychiatr Care 30: 26-31
72. Klee B, Kronig M H (1993) Case report of probable sertraline induced akathisia. Am J Psychiatry 150: 986-987
73. Kline S S, Mauro L S, Scala-Barnett D M, Zick D (1989) Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 8: 510-514
74. Klysner R, Larsen J K, Serensen P, Hyllested M, Pedersen-Dyrlund B (1995) Toxic interaction of venlafaxine and isocarboxazid. Lancet 346: 1298-1299
75. Kuisma M J (1995) Fatal serotonin syndrome with trismus. Ann Emerg Med 26: 108
76. Lane R, Baldwin D (1997) Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 17: 208-221
77. Lappin R I, Auchincloss E L (1994) Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 331: 1021-1022
78. Lejoyeux M, Fineyre F, Ades J (1992) The serotonin syndrome. Am J Psychiatry 149: 1410-1411
79. Lejoyeux M, Rouillon F, Léon E, Adès J (1995) The serotonin syndrome: review of the literature and description of an original study. Encephale 22: 537-543
80. Liebenberg R, Berk M (1996) Serotonergic syndrome after concomitant use of moclobemide and fluoxetine. Hum Psychopharmacol 11: 146-147
81. Lieberman J, Kane J M, Reife R (1985) Neuromuscular effects of monoamine oxidase inhibitors. J Clin Psychopharmacol 5: 221-228
82. London D R, Milne M D (1962) Dangers of monoamine oxidase inhibitors. BMJ 2: 17-52
83. Loveless A H, Maxwell D R (1965) A comparison of the effects of imipramine trimipramine and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol 25: 158-170
84. Marley E, Wozniak K M (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 13: 735-749
85. Marley E, Wozniak K M (1984a) Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 18: 173-189
86. Marley E, Wozniak K M (1984b) Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. J Psychiatr Res 18: 191-203
87. Marley E, Wozniak K M (1985) Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine re-uptake, clomipramine. J Psychiatr Res 19: 597-608
88. Marsden C A, Curzon G (1979) The role of tryptamine in the behavioural effects of tranylcypromine + L-tryptophan. Neuropharmacology 18: 159-164
89. Martin T G (1996) Serotonin syndrome. Ann Emerg Med 28: 520-526
90. Mason B J, Blackburn K H (1997) Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 31: 175-177
91. Mathew N T, Tietjen G E, Lucker C (1996) Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 16: 323-327
92. Mills K C (1995) Serotonin syndrome. Am Fam Physician 52: 1475-1482
93. Mitchell R S (1955) Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 42: 417-424
94. Moller Nielsen I (1980) Tricyclic antidepressants: general pharmacology. In Hofmeister F, Stille G (eds), Psychotropic agents part 1: antipsychotics and antidepressants. Springer-Verlag, Berlin
95. Morch R (1962) Nogle medicamentelt fremkaldte delirose tilstande. Ugeskr Laeger 124: 614-615
96. Muly E C, McDonald W, Steffens D, Book S (1993) Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry 150: 15-65
97. Neuvonen P J, Pohjola-Sintonen S, Tacke U. Vuori E (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342: 14-19
98. Nierenberg D W, Semprebon M (1993) The central nervous system serotonin syndrome. Clin Phamacol Ther 53: 84-88
99. Nimmo S M, Kennedy B W, Tullett W M, Blyth A S, Dougall J R (1993) Drug-induced hyperthermia. Anaesthesia 48: 892-895
100. Nymark M, Moller Neilsen I (1963) Reactions due to the combination of monoamineoxidase inhibitors with thymoleptics, pethidine or methylamphetamine. Lancet 2: 524-525
101. Oates J A, Sjoerdsma A (1960) Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 10: 1076-1078
102. Oefele K V, Grohmann R, Ruther E (1986) Adverse drug reactions in combined tricyclic and MAOI therapy. Pharmacopsychiatry 19: 243-244
103. Ooi TK (1991) The serotonin syndrome. Anaesthesia 46: 507-508
104. Palmer H (1960) Potentiation of pethidine. BMJ 2: 944
105. Papp C, Benaim S (1958) Toxic effects of iproniazid in a patient with angina. BMJ 2: 1070-1072
106. Pato N T, Murphy D L, DeVane C L (1991) Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 11: 224-225
107. Peebles-Brown A E (1985) Hyperpyrexia following psychotropic drug overdose. Anaesthesia 40: 1097-1099
108. Penn R G, Rodgers K J (1971) Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with a monoamine oxidase inhibitor. Br J Pharmacol 42: 485-492
109. Persing J S (1994) Neuroleptic malignant syndrome: an overview. S Dakota J Medicine 47: 51-55
110. Pollock R A, Watson R L (1971) Malignant hyperthermia associated with hypocalcaemia. Anesthesiology 34: 188
111. Power B M, Pinder M, Hackett L P, Ilett K F (1995) Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intens Care 23: 499-502
112. Razani J, White K L, White J, Simpson G, Sloane R B, Rebal R, Palmer R (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 40: 657-661
113. Reeves R, Bullen J (1995) Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 36: 159-160
114. Reid N C R W (1962) Pethidine and phenelzine. BMJ 1: 408
115. Richelson E (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 23: 94-102
116. Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 11: 4-11
117. Richelson E, Souder T, Acuna J, Chou T (1997) Binding studies with some new neuroleptics at human brain receptors. Biol Psychiatry 41: 67S
118. Rivers N, Horner B (1970) Possible lethal interaction between Nardil and dextromethorphan. Can Med Assoc J 103: 85
119. Robert P, Senard J M, Fabre M, Cabot C, Cathala B (1996) Syndrome sérotoninergique lors d'une intoxication aigue aux antidépresseurs. Ann Fr Anesth Réanim 15: 663-665
120. Rogers K J, Thornton J A (1969) The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br J Pharmacol 36: 470-480
121. Rosebush P, Stewart T (1989) A prospective analysis of 24 episodes of neuroleptic syndrome. Am J Psychiatry 149: 717-725
122. Rosenberg M R, Green M (1989) Neuroleptic malignant syndrome: a review of response to therapy. Ann Intern Med 149: 192-731
123. Ruiz F (1994) Fluoxetine and the serotonin syndrome. Ann Emerg Med 24: 983-985
124. Sandyk R (1986) L-Dopa induced serotonin syndrome in a Parkinsonian patient on bromocriptine. J Clin Psychopharmacol 6: 194-195
125. Schuckit M, Robins E, Feighner J (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 24: 509-514
126. Sethna E R (1974) A study of refractory cases of depressive illness and their response to combined antidepressant treatment. Br J Psychiatry 124: 265-272
127. Shee J C (1960) Dangerous potentiation of pethidine by iproniazid and its treatment. BMJ 2: 507-509
128. Sinclair J G (1973) Dextromethorphan monoamine oxidase inhibitor interaction in rabbits. J Pharm Pharmacol 25: 803-808
129. Skop B P, Finkelstein J A, Mareth T R, Magoon M R, Brown T M (1994) The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emergency Med 12: 642-644
130. Snider S R, Hutt C S, Stein B, Fahn S (1975) Increase in brain serotonin produced by bromocriptine. Neurosci Lett 1: 237-241
131. Sovner R, Wolfe J (1988) Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med 319: 16-71
132. Sporer K A (1995) The serotonin syndrome implicated drugs, pathophysiology and management. Drug Safety 13: 94-104
133. Staufenberg E F, Tantum D (1989) Malignant hyperthermia syndrome in combined treatment. Br J Psychiatry 154: 577-578
134. Stern T A, Schwartz J H, Schuster J L (1992) Catastrophic illness associated with the combination of clomipramine, phenelzine, and chlorpromazine. Ann Clin Psychiatry 4: 81-85
135. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148: 705-713
136. Tackley R M, Tregaskis B (1987) Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 42: 760-763
137. Taylor D C (1962) Alarming reaction to pethidine in patients on phenelzine. Lancet 2: 401-402
138. Vigran I M (1964) Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride. JAMA 187: 953-954
139. Wander T J, Nelson A, Okazaki H, Richelson E (1987) Antagonism by neuroleptics of serotonin 5-HT 1 A and 5-HT 2 receptors of normal human brain in vitro. Eur J Pharmacol 143: 279-282
140. White K, Simpson G (1981) Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Pharmacol 1: 264-281
141. Zornberg G L (1993) Adverse interaction between propoxyphene and phenelzine. Am J Psychiatry 150: 1269-1270
142. Zornberg G L, Bodkin J A, Cohen B M (1991) Severe adverse interaction between pethidine and selegiline. Lancet 337: 246